FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2747-2757 December 29, 2005 Number 26 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Swain, S. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen. We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor–positive breast cancer in postmenopausal women.

Methods The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial that compared five years of treatment with various adjuvant endocrine therapy regimens in postmenopausal women with hormone-receptor–positive breast cancer: letrozole, letrozole followed by tamoxifen, tamoxifen, and tamoxifen followed by letrozole. This analysis compares the two groups assigned to receive letrozole initially with the two groups assigned to receive tamoxifen initially; events and follow-up in the sequential-treatment groups were included up to the time that treatments were switched.

Results A total of 8010 women with data that could be assessed were enrolled, 4003 in the letrozole group and 4007 in the tamoxifen group. After a median follow-up of 25.8 months, 351 events had occurred in the letrozole group and 428 events in the tamoxifen group, with five-year disease-free survival estimates of 84.0 percent and 81.4 percent, respectively. As compared with tamoxifen, letrozole significantly reduced the risk of an event ending a period of disease-free survival (hazard ratio, 0.81; 95 percent confidence interval, 0.70 to 0.93; P=0.003), especially the risk of distant recurrence (hazard ratio, 0.73; 95 percent confidence interval, 0.60 to 0.88; P=0.001). Thromboembolism, endometrial cancer, and vaginal bleeding were more common in the tamoxifen group. Women given letrozole had a higher incidence of skeletal and cardiac events and of hypercholesterolemia.

Conclusions In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, reduced the risk of recurrent disease, especially at distant sites. (ClinicalTrials.gov number, NCT00004205 [ClinicalTrials.gov] .)

Source Information

The Writing Committee (Beat Thürlimann, M.D., chair, Aparna Keshaviah, Sc.M., Alan S. Coates, M.D., Henning Mouridsen, M.D., Louis Mauriac, M.D., John F. Forbes, F.R.A.C.S., Robert Paridaens, M.D., Ph.D., Monica Castiglione-Gertsch, M.D., Richard D. Gelber, Ph.D., Manuela Rabaglio, M.D., Ian Smith, M.D., Andrew Wardly, M.D., Karen N. Price, B.S., and Aron Goldhirsch, M.D.) takes responsibility for the content of this article. The affiliations of the Writing Committee members are listed in the Appendix.

Address reprint requests to the International Breast Cancer Study Group Coordinating Center, Effingerstrasse 56, 3088 Bern, Switzerland, or at ibcsg.big198{at}ibcsg.org.

Full Text of this Article

Related Letters:

Letrozole or Tamoxifen in Early Breast Cancer
Buzdar A. U., Baum M., Cuzick J., Erban J. K., Chlebowski R. T., Coates A. S., Mouridsen H., Mauriac L., the BIG 1-98 Collaborative Group
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1528-1530, Apr 6, 2006. Correspondence

This article has been cited by other articles:

• Bonanni, B., Serrano, D., Gandini, S., Guerrieri-Gonzaga, A., Johansson, H., Macis, D., Cazzaniga, M., Luini, A., Cassano, E., Oldani, S., Lien, E. A., Pelosi, G., Decensi, A. (2009). Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia. Clin. Cancer Res. 15: 7053-7060 [Abstract] [Full Text]  
• Trimble, E. L., Abrams, J. S., Meyer, R. M., Calvo, F., Cazap, E., Deye, J., Eisenhauer, E., Fitzgerald, T. J., Lacombe, D., Parmar, M., Seibel, N., Shankar, L., Swart, A. M., Therasse, P., Vikram, B., von Frenckell, R., Friedlander, M., Fujiwara, K., Kaplan, R. S., Meunier, F. (2009). Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. JCO 27: 5109-5114 [Abstract] [Full Text]  
• Dizdar, O., Ozcakar, L., Malas, F. U., Harputluoglu, H., Bulut, N., Aksoy, S., Ozisik, Y., Altundag, K. (2009). Sonographic and Electrodiagnostic Evaluations in Patients With Aromatase Inhibitor-Related Arthralgia. JCO 27: 4955-4960 [Abstract] [Full Text]  
• Schroth, W., Goetz, M. P., Hamann, U., Fasching, P. A., Schmidt, M., Winter, S., Fritz, P., Simon, W., Suman, V. J., Ames, M. M., Safgren, S. L., Kuffel, M. J., Ulmer, H. U., Bolander, J., Strick, R., Beckmann, M. W., Koelbl, H., Weinshilboum, R. M., Ingle, J. N., Eichelbaum, M., Schwab, M., Brauch, H. (2009). Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. JAMA 302: 1429-1436 [Abstract] [Full Text]  
• Filipits, M., Rudas, M., Heinzl, H., Jakesz, R., Kubista, E., Lax, S., Schippinger, W., Dietze, O., Greil, R., Stiglbauer, W., Kwasny, W., Nader, A., Stierer, M., Gnant, M. F.X., for the Austrian Breast and Colorectal Cancer Stud, (2009). Low p27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy. Clin. Cancer Res. 15: 5888-5894 [Abstract] [Full Text]  
• Shuster, M., Peterson, K. (2009). Development, Implementation, and Assessment of a Lecture Course on Cancer for Undergraduates. cellbioed 8: 193-202 [Abstract] [Full Text]  
• Bedard, P. L., Body, J.-J., Piccart-Gebhart, M. J. (2009). Sowing the Soil for Cure? Results of the ABCSG-12 Trial Open a New Chapter in the Evolving Adjuvant Bisphosphonate Story in Early Breast Cancer. JCO 27: 4043-4046 [Full Text]  
• Rabaglio, M., Sun, Z., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thurlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J., Colleoni, M., Pienkowski, T., Nogaret, J.-M., Lang, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S., for the BIG 1-98 Collaborative and International B, (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 20: 1489-1498 [Abstract] [Full Text]  
• The BIG 1-98 Collaborative Group, (2009). Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. NEJM 361: 766-776 [Abstract] [Full Text]  
• Mohamed, I., Yeh, J. K (2009). Alfacalcidol prevents aromatase inhibitor (Letrozole)-induced bone mineral loss in young growing female rats. J Endocrinol 202: 317-325 [Abstract] [Full Text]  
• Bramwell, V. H. C., Pritchard, K. I., Tu, D., Tonkin, K., Vachhrajani, H., Vandenberg, T. A., Robert, J., Arnold, A., O'Reilly, S. E., Graham, B., Shepherd, L. (2009). A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12). Ann Oncol 0: mdp326v1-mdp326 [Abstract] [Full Text]  
• Kimmick, G., Anderson, R., Camacho, F., Bhosle, M., Hwang, W., Balkrishnan, R. (2009). Adjuvant Hormonal Therapy Use Among Insured, Low-Income Women With Breast Cancer. JCO 27: 3445-3451 [Abstract] [Full Text]  
• Lin, B. C., Suzawa, M., Blind, R. D., Tobias, S. C., Bulun, S. E., Scanlan, T. S., Ingraham, H. A. (2009). Stimulating the GPR30 Estrogen Receptor with a Novel Tamoxifen Analogue Activates SF-1 and Promotes Endometrial Cell Proliferation. Cancer Res. 69: 5415-5423 [Abstract] [Full Text]  
• Lin, C.-H., Liau, J.-Y., Lu, Y.-S., Huang, C.-S., Lee, W.-C., Kuo, K.-T., Shen, Y.-C., Kuo, S.-H., Lan, C., Liu, J. M., Kuo, W.-H., Chang, K.-J., Cheng, A.-L. (2009). Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia. Cancer Epidemiol. Biomarkers Prev. 18: 1807-1814 [Abstract] [Full Text]  
• Buzdar, A. U. (2009). Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol 20: 993-999 [Abstract] [Full Text]  
• Kataja, V., Castiglione, M., On behalf of the ESMO Guidelines Working Group, (2009). Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv10-iv14 [Full Text]  
• Azuma, K., Urano, T., Horie-Inoue, K., Hayashi, S.-i., Sakai, R., Ouchi, Y., Inoue, S. (2009). Association of Estrogen Receptor {alpha} and Histone Deacetylase 6 Causes Rapid Deacetylation of Tubulin in Breast Cancer Cells. Cancer Res. 69: 2935-2940 [Abstract] [Full Text]  
• KULENDRAN, M., SALHAB, M., MOKBEL, K. (2009). Oestrogen-Synthesising Enzymes and Breast Cancer. Anticancer Res 29: 1095-1109 [Abstract] [Full Text]  
• Russell, N. S., Kunkler, I. H., van Tienhoven, G., Canney, P. A., Thomas, J., Bartlett, J., van de Vijver, M. J., Belkacemi, Y., Yarnold, J. R., Barrett-Lee, P. J. (2009). Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?. JCO 27: 996-997 [Full Text]  
• Jordan, V. C. (2009). A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention. Cancer Res. 69: 1243-1254 [Abstract] [Full Text]  
• Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., Samonigg, H., Tausch, C., Eidtmann, H., Steger, G., Kwasny, W., Dubsky, P., Fridrik, M., Fitzal, F., Stierer, M., Rucklinger, E., Greil, R., the ABCSG-12 Trial Investigators, (2009). Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. NEJM 360: 679-691 [Abstract] [Full Text]  
• Kleinberg, D. L., Wood, T. L., Furth, P. A., Lee, A. V. (2009). Growth Hormone and Insulin-Like Growth Factor-I in the Transition from Normal Mammary Development to Preneoplastic Mammary Lesions. Endocr. Rev. 30: 51-74 [Abstract] [Full Text]  
• Markopoulos, C., Polychronis, A., Dafni, U., Koukouras, D., Zobolas, V., Tzorakoleftherakis, E., Xepapadakis, G., Gogas, H. (2009). Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol 20: 49-55 [Abstract] [Full Text]  
• Irwin, M L (2009). Physical activity interventions for cancer survivors. Br. J. Sports. Med. 43: 32-38 [Abstract] [Full Text]  
• Viale, G., Giobbie-Hurder, A., Regan, M. M., Coates, A. S., Mastropasqua, M. G., Dell'Orto, P., Maiorano, E., MacGrogan, G., Braye, S. G., Ohlschlegel, C., Neven, P., Orosz, Z., Olszewski, W. P., Knox, F., Thurlimann, B., Price, K. N., Castiglione-Gertsch, M., Gelber, R. D., Gusterson, B. A., Goldhirsch, A. (2008). Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. JCO 26: 5569-5575 [Abstract] [Full Text]  
• Berruti, A., Brizzi, M. P., Generali, D., Ardine, M., Dogliotti, L., Bruzzi, P., Bottini, A. (2008). Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions. The Oncologist 13: 1137-1148 [Abstract] [Full Text]  
• Ellis, G. K., Bone, H. G., Chlebowski, R., Paul, D., Spadafora, S., Smith, J., Fan, M., Jun, S. (2008). Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer. JCO 26: 4875-4882 [Abstract] [Full Text]  
• Paridaens, R. J., Dirix, L. Y., Beex, L. V., Nooij, M., Cameron, D. A., Cufer, T., Piccart, M. J., Bogaerts, J., Therasse, P. (2008). Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. JCO 26: 4883-4890 [Abstract] [Full Text]  
• Foster, P. A., Chander, S. K., Newman, S. P., Woo, L.W. L., Sutcliffe, O. B., Bubert, C., Zhou, D., Chen, S., Potter, B. V.L., Reed, M. J., Purohit, A. (2008). A New Therapeutic Strategy against Hormone-Dependent Breast Cancer: The Preclinical Development of a Dual Aromatase and Sulfatase Inhibitor. Clin. Cancer Res. 14: 6469-6477 [Abstract] [Full Text]  
• Geisler, J., Helle, H., Ekse, D., Duong, N. K., Evans, D. B., Nordbo, Y., Aas, T., Lonning, P. E. (2008). Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clin. Cancer Res. 14: 6330-6335 [Abstract] [Full Text]  
• Lester, J. E., Dodwell, D., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., Horsman, J. M., Brown, J. E., Hannon, R. A., Coleman, R. E. (2008). Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer. Clin. Cancer Res. 14: 6336-6342 [Abstract] [Full Text]  
• Newman, W. G., Hadfield, K. D., Latif, A., Roberts, S. A., Shenton, A., McHague, C., Lalloo, F., Howell, S., Evans, D. G. (2008). Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients. Clin. Cancer Res. 14: 5913-5918 [Abstract] [Full Text]  
• Saarto, T., Vehmanen, L., Blomqvist, C., Elomaa, I. (2008). Ten-Year Follow-Up of 3 Years of Oral Adjuvant Clodronate Therapy Shows Significant Prevention of Osteoporosis in Early-Stage Breast Cancer. JCO 26: 4289-4295 [Abstract] [Full Text]  
• McElroy, J. A., Shafer, M. M., Gangnon, R. E., Crouch, L. A., Newcomb, P. A. (2008). Urinary Lead Exposure and Breast Cancer Risk in a Population-Based Case-Control Study. Cancer Epidemiol. Biomarkers Prev. 17: 2311-2317 [Abstract] [Full Text]  
• Samaddar, J. S., Gaddy, V. T., Duplantier, J., Thandavan, S. P., Shah, M., Smith, M. J., Browning, D., Rawson, J., Smith, S. B., Barrett, J. T., Schoenlein, P. V. (2008). A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Molecular Cancer Therapeutics 7: 2977-2987 [Abstract] [Full Text]  
• Ryberg, M., Nielsen, D., Cortese, G., Nielsen, G., Skovsgaard, T., Andersen, P. K. (2008). New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients. JNCI J Natl Cancer Inst 100: 1058-1067 [Abstract] [Full Text]  
• Hadji, P., Body, J. -J., Aapro, M. S., Brufsky, A., Coleman, R. E., Guise, T., Lipton, A., Tubiana-Hulin, M. (2008). Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19: 1407-1416 [Abstract] [Full Text]  
• Chu, Q. S.C., Cianfrocca, M. E., Goldstein, L. J., Gale, M., Murray, N., Loftiss, J., Arya, N., Koch, K. M., Pandite, L., Fleming, R. A., Paul, E., Rowinsky, E. K. (2008). A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer. Clin. Cancer Res. 14: 4484-4490 [Abstract] [Full Text]  
• Morales, L., Pans, S., Verschueren, K., Van Calster, B., Paridaens, R., Westhovens, R., Timmerman, D., De Smet, L., Vergote, I., Christiaens, M.-R., Neven, P. (2008). Prospective Study to Assess Short-Term Intra-Articular and Tenosynovial Changes in the Aromatase Inhibitor-Associated Arthralgia Syndrome. JCO 26: 3147-3152 [Abstract] [Full Text]  
• Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., Colwell, C. W. (2008). Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 381S-453S [Abstract] [Full Text]  
• Song, H., Shahverdi, K., Huso, D. L., Esaias, C., Fox, J., Liedy, A., Zhang, Z., Reilly, R. T., Apostolidis, C., Morgenstern, A., Sgouros, G. (2008). 213Bi ({alpha}-Emitter)-Antibody Targeting of Breast Cancer Metastases in the neu-N Transgenic Mouse Model. Cancer Res. 68: 3873-3880 [Abstract] [Full Text]  
• Hayes, D. F., Stearns, V., Rae, J., Flockhart, D., on behalf of the Consortium on Breast Cancer Pharm, (2008). A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients?. JNCI J Natl Cancer Inst 100: 610-613 [Full Text]  
• Mamounas, E. P., Jeong, J.-H., Wickerham, D. L., Smith, R. E., Ganz, P. A., Land, S. R., Eisen, A., Fehrenbacher, L., Farrar, W. B., Atkins, J. N., Pajon, E. R., Vogel, V. G., Kroener, J. F., Hutchins, L. F., Robidoux, A., Hoehn, J. L., Ingle, J. N., Geyer, C. E. Jr, Costantino, J. P., Wolmark, N. (2008). Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. JCO 26: 1965-1971 [Abstract] [Full Text]  
• Crivellari, D., Sun, Z., Coates, A. S., Price, K. N., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R. J., Castiglione-Gertsch, M., Gelber, R. D., Colleoni, M., Lang, I., Del Mastro, L., Gladieff, L., Rabaglio, M., Smith, I. E., Chirgwin, J. H., Goldhirsch, A. (2008). Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial. JCO 26: 1972-1979 [Abstract] [Full Text]  
• Lin, N. U., Winer, E. P. (2008). Optimizing Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: Treating the Right Patients for the Right Length of Time. JCO 26: 1919-1921 [Full Text]  
• Kendall, A., Anderson, H., Dunbier, A. K., Mackay, A., Dexter, T., Urruticoechea, A., Harper-Wynne, C., Dowsett, M. (2008). Impact of Estrogen Deprivation on Gene Expression Profiles of Normal Postmenopausal Breast Tissue In vivo. Cancer Epidemiol. Biomarkers Prev. 17: 855-863 [Abstract] [Full Text]  
• Dixon, J. M., Renshaw, L., Young, O., Murray, J., Macaskill, E. J., McHugh, M., Folkerd, E., Cameron, D. A., A'Hern, R. P., Dowsett, M. (2008). Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer. JCO 26: 1671-1676 [Abstract] [Full Text]  
• Chia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., Fein, L., Romieu, G., Buzdar, A., Robertson, J. F.R., Brufsky, A., Possinger, K., Rennie, P., Sapunar, F., Lowe, E., Piccart, M. (2008). Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results From EFECT. JCO 26: 1664-1670 [Abstract] [Full Text]  
• Rudas, M., Lehnert, M., Huynh, A., Jakesz, R., Singer, C., Lax, S., Schippinger, W., Dietze, O., Greil, R., Stiglbauer, W., Kwasny, W., Grill, R., Stierer, M., Gnant, M. F.X., Filipits, M., for the Austrian Breast and Colorectal Cancer Stud, (2008). Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. Clin. Cancer Res. 14: 1767-1774 [Abstract] [Full Text]  
• Farag, N., Burns, R., Come, S. E. (2008). Update: A 62-Year-Old Woman With a New Diagnosis of Breast Cancer. JAMA 299: 1055-1056 [Full Text]  
• Hadji, P (2008). Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 15: 73-90 [Abstract] [Full Text]  
• Eastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J., Mackey, J. R., Beckmann, M. W., Clack, G. (2008). Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. JCO 26: 1051-1057 [Abstract] [Full Text]  
• Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crino, L., Dirix, L., Gnant, M., Gralow, J., Hadji, P., Hortobagyi, G. N., Jonat, W., Lipton, A., Monnier, A., Paterson, A. H. G., Rizzoli, R., Saad, F., Thurlimann, B. (2008). Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19: 420-432 [Abstract] [Full Text]  
• Ng, R., Pond, G. R., Tang, P. A., MacIntosh, P. W., Siu, L. L., Chen, E. X. (2008). Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol 19: 481-486 [Abstract] [Full Text]  
• Trinkaus, M., Chin, S., Wolfman, W., Simmons, C., Clemons, M. (2008). Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?. The Oncologist 13: 222-231 [Abstract] [Full Text]  
• Parton, M., Smith, I. E. (2008). Controversies in the Management of Patients With Breast Cancer: Adjuvant Endocrine Therapy in Premenopausal Women. JCO 26: 745-752 [Full Text]  
• Lin, N. U., Winer, E. P. (2008). Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. JCO 26: 798-805 [Abstract] [Full Text]  
• Greene, R. E., Tsang, V. (2008). Hormonal Therapy for the Treatment of Postmenopausal Breast Cancer Patients. Journal of Pharmacy Practice 21: 36-45 [Abstract]  
• Kahn, K. L. (2008). Moving Research From Bench to Bedside to Community: There Is Still More to Do. JCO 26: 523-526 [Full Text]  
• Rossi, E., Morabito, A., De Maio, E., Di Rella, F., Esposito, G., Gravina, A., Labonia, V., Landi, G., Nuzzo, F., Pacilio, C., Piccirillo, M. C., D'Aiuto, G., D'Aiuto, M., Rinaldo, M., Botti, G., Gallo, C., Perrone, F., de Matteis, A. (2008). Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer. JCO 26: 264-270 [Abstract] [Full Text]  
• Bruzzi, P. (2008). Non-drug industry funded research. BMJ 336: 1-2 [Full Text]  
• Rugo, H. S. (2008). The breast cancer continuum in hormone-receptor positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 19: 16-27 [Abstract] [Full Text]  
• Bird, B. R.J. H., Swain, S. M. (2008). Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems. Clin. Cancer Res. 14: 14-24 [Abstract] [Full Text]  
• Pritchard, K. I. (2008). Adjuvant Endocrine Therapy of the Future: Potential and Possibilities. Am Soc Clin Oncol Ed Book 2008: 18-23 [Abstract] [Full Text]  
• Bakkum-Gamez, J. N., Gonzalez-Bosquet, J., Laack, N. N., Mariani, A., Dowdy, S. C. (2008). Current Issues in the Management of Endometrial Cancer. Mayo Clin Proc. 83: 97-112 [Abstract] [Full Text]  
• Jordan, V. C., O'Malley, B. W. (2007). Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer. JCO 25: 5815-5824 [Abstract] [Full Text]  
• Mouridsen, H., Keshaviah, A., Coates, A. S., Rabaglio, M., Castiglione-Gertsch, M., Sun, Z., Thurlimann, B., Mauriac, L., Forbes, J. F., Paridaens, R., Gelber, R. D., Colleoni, M., Smith, I., Price, K. N., Goldhirsch, A. (2007). Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial. JCO 25: 5715-5722 [Abstract] [Full Text]  
• Prowell, T. M., Stearns, V. (2007). Extended Adjuvant Therapy for Breast Cancer How Much Is Enough?. JNCI J Natl Cancer Inst 99: 1825-1827 [Full Text]  
• Jones, L. W., Haykowsky, M., Pituskin, E. N., Jendzjowsky, N. G., Tomczak, C. R., Haennel, R. G., Mackey, J. R. (2007). Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor Positive Operable Breast Cancer. The Oncologist 12: 1156-1164 [Abstract] [Full Text]  
• Blackburn, G. L, Wang, K. A (2007). Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS). Am. J. Clin. Nutr. 86: 878S-881S [Abstract] [Full Text]  
• Dedes, K., Szucs, T., Imesch, P, Fedier, A, Fehr, M., Fink, D (2007). Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol 18: 1493-1499 [Abstract] [Full Text]  
• Viale, G., Regan, M. M., Maiorano, E., Mastropasqua, M. G., Dell'Orto, P., Rasmussen, B. B., Raffoul, J., Neven, P., Orosz, Z., Braye, S., Ohlschlegel, C., Thurlimann, B., Gelber, R. D., Castiglione-Gertsch, M., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S. (2007). Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98. JCO 25: 3846-3852 [Abstract] [Full Text]  
• Pruthi, S., Boughey, J. C., Brandt, K. R., Degnim, A. C., Dy, G. K., Goetz, M. P., Perez, E. A., Reynolds, C. A., Schomberg, P. J., Ingle, J. N. (2007). A Multidisciplinary Approach to the Management of Breast Cancer, Part 2: Therapeutic Considerations. Mayo Clin Proc. 82: 1131-1140 [Abstract] [Full Text]  
• Pietras, R. J., Marquez-Garban, D. C. (2007). Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers. Clin. Cancer Res. 13: 4672-4676 [Full Text]  
• Gralow, J. R. (2007). Bone Density in Breast Cancer: When to Intervene?. JCO 25: 3194-3197 [Full Text]  
• Kaufmann, M., Jonat, W., Hilfrich, J., Eidtmann, H., Gademann, G., Zuna, I., von Minckwitz, G. (2007). Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study. JCO 25: 2664-2670 [Abstract] [Full Text]  
• Lin, N. U., Winer, E. P. (2007). Optimal Use of Aromatase Inhibitors: To Lead or to Follow?. JCO 25: 2639-2641 [Full Text]  
• Azim, A. A., Costantini-Ferrando, M., Lostritto, K., Oktay, K. (2007). Relative Potencies of Anastrozole and Letrozole to Suppress Estradiol in Breast Cancer Patients Undergoing Ovarian Stimulation before in Vitro Fertilization. J. Clin. Endocrinol. Metab. 92: 2197-2200 [Abstract] [Full Text]  
• Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., Zujewski, J. A. (2007). Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. JCO 25: 2127-2132 [Abstract] [Full Text]  
• Buzdar, A. U. (2007). Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Breast Cancer. JCO 25: 2147-2148 [Full Text]  
• Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., Livingston, R. B., Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Cameron, D. A., Palmer, M. J., Pater, J. L. (2007). Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. JCO 25: 2006-2011 [Abstract] [Full Text]  
• Jordan, V. C., Gelber, R. D. (2007). Problems With the Progesterone Receptor in Practice?. JCO 25: 1957-1959 [Full Text]  
• Muss, H. B., Biganzoli, L., Sargent, D. J., Aapro, M. (2007). Adjuvant Therapy in the Elderly: Making the Right Decision. JCO 25: 1870-1875 [Abstract] [Full Text]  
• Crivellari, D., Aapro, M., Leonard, R., von Minckwitz, G., Brain, E., Goldhirsch, A., Veronesi, A., Muss, H. (2007). Breast Cancer in the Elderly. JCO 25: 1882-1890 [Abstract] [Full Text]  
• Garg, A., Simha, V. (2007). Update on Dyslipidemia. J. Clin. Endocrinol. Metab. 92: 1581-1589 [Abstract] [Full Text]  
• Buzdar, A. U. (2007). Adjuvant Chemotherapy for High-Risk Operable Breast Cancer. JCO 25: 1642-1644 [Full Text]  
• Mauriac, L, Keshaviah, A, Debled, M, Mouridsen, H, Forbes, J., Thurlimann, B, Paridaens, R, Monnier, A, Lang, I, Wardley, A, Nogaret, J-M, Gelber, R., Castiglione-Gertsch, M, Price, K., Coates, A., Smith, I, Viale, G, Rabaglio, M, Zabaznyi, N, Goldhirsch, A, On the behalf of BIG 1-98 Collaborative Group and, (2007). Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18: 859-867 [Abstract] [Full Text]  
• Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Harris, A., Bergh, J., Foekens, J. A., Klijn, J. G.M., Larsimont, D., Buyse, M., Bontempi, G., Delorenzi, M., Piccart, M. J., Sotiriou, C. (2007). Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade. JCO 25: 1239-1246 [Abstract] [Full Text]  
• Wood, C. E., Register, T. C., Cline, J.M. (2007). Soy isoflavonoid effects on endogenous estrogen metabolism in postmenopausal female monkeys. Carcinogenesis 28: 801-808 [Abstract] [Full Text]